CDMOs play an essential role in supporting peptide New Chemical Entities (NCEs) from early development through to commercialization. The global CDMO Service for Peptide APIs market was valued at US$ 3,986 million in 2025 and is anticipated to reach US$ 13,186 million by 2032[reference:147], reflecting the growing reliance on CDMOs for peptide development.
In early development, CDMOs provide route scouting and feasibility studies to identify the most efficient synthesis route. They produce toxicology batches for preclinical studies, with appropriate quality and documentation. They also provide analytical method development and stability studies to support IND filings.
In clinical development, CDMOs scale up production to meet the demands of Phase I-III trials. They validate the manufacturing process, conduct stability studies, and provide comprehensive documentation for regulatory submissions. They also support formulation development and tech transfer to commercial manufacturing sites.
In commercialization, CDMOs provide commercial supply of peptide APIs, with robust quality systems and supply chain management. They support regulatory filings with comprehensive documentation and respond to regulatory inquiries. They also provide continuous improvement and life cycle management for approved products.
Key capabilities that CDMOs provide include synthesis, purification, analytical testing, and regulatory support. The integrated approach de-risks development by providing a single point of accountability and reducing technology transfer risks. At PeptideHub, our comprehensive services ensure seamless progression from early development through to commercialization, with full regulatory documentation and supply chain management.